Login

Switch On Your HIV Smarts.

Author Archives: Liz Highleyman

In a class of its own, “uniquely potent” HIV capsid inhibitor thwarts HIV replication

In a class of its own, “uniquely potent” HIV capsid inhibitor thwarts HIV replication

, by Liz Highleyman

Promising research about a new type of HIV drug called GS-CA1, the first capsid inhibitor to enter clinical trials, was shared at CROI 2017. Read More

Antibody therapies effective at preventing HIV from invading CD4 cells

Antibody therapies effective at preventing HIV from invading CD4 cells

, by Liz Highleyman

Research on two new long-acting antibody therapies demonstrates success at protecting CD4 cells and suppressing viral loads in people living with HIV. Read More

Two new HIV drugs, Doravirine and Bictegravir, suppress viral loads in studies and proceed to Phase 3 testing

Two new HIV drugs, Doravirine and Bictegravir, suppress viral loads in studies and proceed to Phase 3 testing

, by Liz Highleyman

Two new HIV drugs, an NNRTI and an integrase inhibitor, did well in clinical trials and are currently being tested as part of fixed-dose co-formulated pills. Read More

Simpler HIV treatment, with only 2 drugs, keeps viral loads suppressed

Simpler HIV treatment, with only 2 drugs, keeps viral loads suppressed

, by Liz Highleyman

People taking only two drugs, dolutegravir and rilpivirine, maintained viral suppression in participants of the SWORD-1 an SWORD-2 studies. Read More

Timothy Brown, the Berlin Patient, Celebrates a Decade Cured of HIV

Timothy Brown, the Berlin Patient, Celebrates a Decade Cured of HIV

, by Liz Highleyman

The only person cured of HIV, Brown now takes Truvada as PrEP to prevent a new HIV infection. Read More